Why the study?
Does systemic versus local Angiotensin II infusion alter uterine vascular resistance and blood flow in pregnant and nonpregnant ewes?
Does systemic versus local Angiotensin II infusion alter uterine vascular resistance and blood flow in pregnant and nonpregnant ewes?
Systemic Angiotensin II increases uterine vascular resistance indirectly, likely through the release of other vasoconstrictors, with attenuated responses during pregnancy.
Answers are grounded in this paper and cite their sources.
Indicates indirect systemic ANG II effects on uterine vasculature in ewes; hypothesis-generating for pregnancy-attenuated responses pending human studies.
The uterine vasculature of women and sheep predominantly expresses type 2 ANG II receptors that do not mediate vasoconstriction. Although systemic ANG II infusions increase uterine vascular resistance (UVR), this could reflect indirect mechanisms. Thus we compared systemic and local intra-arterial ANG II infusions in six near-term pregnant and five ovariectomized nonpregnant ewes to determine how ANG II increases UVR. Systemic ANG II dose-dependently (P > 0.001) increased arterial pressure (MAP) and UVR and decreased uterine blood flow (UBF) in pregnant and nonpregnant ewes; however, nonpregnant responses exceeded pregnant (P < 0.001). In contrast, local ANG II infusions at rates designed to achieve concentrations in the uterine circulation comparable to those seen during systemic infusions did not significantly decrease UBF in either group, and changes in MAP and UVR were absent or markedly attenuated. When MAP rose during local ANG II, which only occurred with doses > or =2 ng/ml, increases in MAP were delayed more than twofold compared with responses during systemic ANG II infusions and always preceded decreases in UBF, resembling that observed during systemic ANG II infusions. These observations demonstrate attenuated uterine vascular responses to systemic ANG II during pregnancy and suggest that systemic ANG II may increase UVR through release of another potent vasoconstrictor(s) into the systemic circulation.
No takes yet. Share an insight, caveat, or question.
Cox et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: